MedTrace Logo

Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

NCT06392763 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 602

Last updated 2024-04-30

No results posted yet for this study

Summary

This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.

Conditions

  • Diffuse Large B-cell Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-03
Primary Completion
2023-04-28
Completion
2023-04-28

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06392763 on ClinicalTrials.gov